Osteoprotegerin and RANKL serum concentrations in neonates of mothers with early-onset pre-eclampsia: comparison with neonates of normotensive mothers.


Journal

Early human development
ISSN: 1872-6232
Titre abrégé: Early Hum Dev
Pays: Ireland
ID NLM: 7708381

Informations de publication

Date de publication:
08 2019
Historique:
received: 16 03 2019
revised: 30 05 2019
accepted: 01 06 2019
pubmed: 9 6 2019
medline: 6 2 2020
entrez: 9 6 2019
Statut: ppublish

Résumé

Pre-eclampsia is a known risk factor for long-term cardiovascular complications. Osteoprotegerin (OPG) and the receptor activator of nuclear factor κB ligand (RANKL) have been implicated in the pathogenesis of cardiovascular disease. The OPG-RANKL axis function is also altered in pregnant women with pre-eclampsia, but there is lack of data regarding OPG and RANKL concentrations in their neonates. To examine the effects of early-onset pre-eclampsia on OPG and RANKL serum concentrations at birth, taking into account the influence of various perinatal factors. OPG and RANKL serum concentrations were measured in 28 premature newborns of mothers with early onset pre-eclampsia, and in 28 preterm and 28 full-term neonates of normotensive mothers (control groups). Neonates of pre-eclamptic mothers had higher OPG and lower RANKL levels compared to both control groups (Kruskal-Wallis P < 0.0001 and P = 0.014, respectively). Regression analysis showed that pre-eclampsia (P < 0.0001), birth weight z-score (P = 0.048) and antenatal steroid administration (P = 0.034) were significant determinants of OPG levels. Multivariable regression analysis also showed that pre-eclampsia was an independent predictor of increased diastolic and mean blood pressure in these neonates. Early-onset pre-eclampsia affects OPG concentrations at birth and is an independent predictor of increased blood pressure in the offspring. Our findings suggest that altered OPG-RANKL axis function may be one of the mechanisms of cardiovascular 'programming' in fetuses exposed to pre-eclampsia.

Sections du résumé

BACKGROUND
Pre-eclampsia is a known risk factor for long-term cardiovascular complications. Osteoprotegerin (OPG) and the receptor activator of nuclear factor κB ligand (RANKL) have been implicated in the pathogenesis of cardiovascular disease. The OPG-RANKL axis function is also altered in pregnant women with pre-eclampsia, but there is lack of data regarding OPG and RANKL concentrations in their neonates.
AIMS
To examine the effects of early-onset pre-eclampsia on OPG and RANKL serum concentrations at birth, taking into account the influence of various perinatal factors.
STUDY DESIGN
OPG and RANKL serum concentrations were measured in 28 premature newborns of mothers with early onset pre-eclampsia, and in 28 preterm and 28 full-term neonates of normotensive mothers (control groups).
RESULTS
Neonates of pre-eclamptic mothers had higher OPG and lower RANKL levels compared to both control groups (Kruskal-Wallis P < 0.0001 and P = 0.014, respectively). Regression analysis showed that pre-eclampsia (P < 0.0001), birth weight z-score (P = 0.048) and antenatal steroid administration (P = 0.034) were significant determinants of OPG levels. Multivariable regression analysis also showed that pre-eclampsia was an independent predictor of increased diastolic and mean blood pressure in these neonates.
CONCLUSIONS
Early-onset pre-eclampsia affects OPG concentrations at birth and is an independent predictor of increased blood pressure in the offspring. Our findings suggest that altered OPG-RANKL axis function may be one of the mechanisms of cardiovascular 'programming' in fetuses exposed to pre-eclampsia.

Identifiants

pubmed: 31176082
pii: S0378-3782(19)30130-6
doi: 10.1016/j.earlhumdev.2019.06.001
pii:
doi:

Substances chimiques

Biomarkers 0
Osteoprotegerin 0
RANK Ligand 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-5

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Nikoleta Oikonomou (N)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece.

Chrysanthi Papadopoulou (C)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece.

Sotirios Fouzas (S)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece. Electronic address: sfouzas@upatras.gr.

Dimitra Kritikou (D)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece.

Dionisios Chrysis (D)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece.

Xenophon Sinopidis (X)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece.

Gabriel Dimitriou (G)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece.

Ageliki A Karatza (AA)

Department of Pediatrics, Neonatal Intensive Care Unit, University of Patras Medical School, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH